TriSalus Life Sciences (TLSI) Net Margin (2022 - 2026)

TriSalus Life Sciences has reported Net Margin for 5 years, with the latest figure at 17.29% in Q1 2026.

• For the quarter ending Q1 2026, Net Margin rose 13824.0% year-over-year to 17.29%; the trailing twelve-month figure through Mar 2026 stood at 130.32% (down 3600.0% YoY), and the FY2025 full-year result was 154.35%, down 4143.0% from the prior year.
• Net Margin for Q1 2026 stood at 17.29%, up from 73.86% in the prior quarter.
• The five-year high for Net Margin was 17.29% in Q1 2026, with the low at 786.45% in Q4 2022.
• Historically, Net Margin has averaged 226.58% across 5 years, with a median of 131.84% in 2024.
• Annual changes were most pronounced in 2024 — Net Margin surged 50510 bps — and 2025, when it sank 31329 bps.
• TriSalus Life Sciences' Net Margin stood at 786.45% in 2022, then gained by 19 bps to 636.93% in 2023, then surged by 79 bps to 131.84% in 2024, then jumped by 44 bps to 73.86% in 2025, then soared by 123 bps to 17.29% in 2026.
• The last three Net Margin figures came in at 17.29% (Q1 2026), 73.86% (Q4 2025), and 356.86% (Q3 2025), per Business Quant data.